BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28539357)

  • 1. Novel association of
    Kim DS; Jackson AU; Li YK; Stringham HM; Kuusisto J; Kangas AJ; Soininen P; Ala-Korpela M; Burant CF; Salomaa V; Boehnke M; Laakso M; Speliotes EK
    J Lipid Res; 2017 Jul; 58(7):1471-1481. PubMed ID: 28539357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis.
    Li XY; Liu Z; Li L; Wang HJ; Wang H
    Front Endocrinol (Lausanne); 2022; 13():1026901. PubMed ID: 36353245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.
    Goffredo M; Caprio S; Feldstein AE; D'Adamo E; Shaw MM; Pierpont B; Savoye M; Zhao H; Bale AE; Santoro N
    Hepatology; 2016 Jan; 63(1):117-25. PubMed ID: 26457389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.
    Li Y; Liu S; Gao Y; Ma H; Zhan S; Yang Y; Xin Y; Xuan S
    BMC Biochem; 2019 Feb; 20(1):3. PubMed ID: 30727943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.
    Pirola CJ; Sookoian S
    Hepatology; 2015 Dec; 62(6):1742-56. PubMed ID: 26331730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.
    Musso G; Cipolla U; Cassader M; Pinach S; Saba F; De Michieli F; Paschetta E; Bongiovanni D; Framarin L; Leone N; Berrutti M; Rosina F; Corvisieri S; Molinaro F; Sircana A; Gambino R
    J Lipid Res; 2017 Jun; 58(6):1221-1229. PubMed ID: 28242789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.
    Xia Y; Huang CX; Li GY; Chen KH; Han L; Tang L; Luo HQ; Bao MH
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):533-541. PubMed ID: 30824369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
    Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
    Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.
    Xue WY; Zhang L; Liu CM; Gao Y; Li SJ; Huai ZY; Dai J; Wang YY
    Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):97-107. PubMed ID: 35057689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
    Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
    Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
    Bódis K; Bombrich M; Schön M; Knebel B; Zaharia OP; Bönhof G; Karusheva Y; Strassburger K; Kupriyanova Y; Kotzka J; Guthoff R; Schrauwen-Hinderling V; Al-Hasani H; Burkart V; Szendroedi J; Wagner R; Markgraf DF; Roden M;
    Nutr Metab Cardiovasc Dis; 2023 Sep; 33(9):1785-1796. PubMed ID: 37495452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
    Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
    PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
    O'Hare EA; Yang R; Yerges-Armstrong LM; Sreenivasan U; McFarland R; Leitch CC; Wilson MH; Narina S; Gorden A; Ryan KA; Shuldiner AR; Farber SA; Wood GC; Still CD; Gerhard GS; Robishaw JD; Sztalryd C; Zaghloul NA
    Hepatology; 2017 May; 65(5):1526-1542. PubMed ID: 28027591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
    Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
    Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice.
    Fan Y; Lu H; Guo Y; Zhu T; Garcia-Barrio MT; Jiang Z; Willer CJ; Zhang J; Chen YE
    Gastroenterology; 2016 May; 150(5):1208-1218. PubMed ID: 26774178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.